Search Results

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.

Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.

AVITA Medical, Inc. announced that the U.S. Food and Drug Administration has approved its premarket approval supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects.

GenomOncology revealed an upgraded version of GO Pathology Workbench, their software platform for tertiary analysis and reporting of next generation sequencing and other molecular testing results.

AVITA Medical, Inc., a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, announced that the Joseph M. Still Burn Center at Doctors Hospital of Augusta is the first U.S. burn center to treat a patient using its RECELL GO™ System.

Soterix Medical Inc., the global leader in non-invasive brain stimulation and synergistic monitoring technologies, announced the launch of MxN-GO EEG, a combined High Definition transcranial Electrical Stimulation and EEG system with a unique untethered design.